Royalty Pharma Reports Second Quarter 2024 Results
NEW YORK, NY, August 8, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts.
News
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
NEW YORK, NY, July 24, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital.
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
NEW YORK, NY, July 19, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Royalty Pharma Declares Third Quarter 2024 Dividend
NEW YORK, NY, July 17, 2024 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share.
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
NEW YORK, NY, June 4, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET.
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
NEW YORK, NY, June 3, 2024 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”)
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
NEW YORK, NY, May 28, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an interest in Agios Pharmaceuticals’ royalty on Servier’s vorasidenib for $905 million in upfront cash contingent on U.S. Food and Drug Administration (FDA) approval of vorasidenib.
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
NEW YORK, NY and SOUTH SAN FRANCISCO, CA, May 22, 2024 – Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, NY, May 13, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in upcoming investor conferences during the month of May.
Royalty Pharma Reports First Quarter 2024 Results
NEW YORK, NY, May 9, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts.
